Whittier, CALIFORNIA2 Active Studies

Myeloproliferative Neoplasms Clinical Trials in Whittier, CALIFORNIA

Find 2 actively recruiting myeloproliferative neoplasms clinical trials in Whittier, CALIFORNIA. Connect with local research sites and explore new treatment options.

2
Active Trials
1
Sponsors
437
Enrolling

Recruiting Myeloproliferative Neoplasms Studies in Whittier

About Myeloproliferative Neoplasms Clinical Trials in Whittier

Myeloproliferative neoplasms (MPNs) are blood cancers in which the bone marrow overproduces red blood cells, platelets, or white blood cells. Types include polycythemia vera, essential thrombocythemia, and myelofibrosis. Treatment depends on the specific type and risk factors.

There are currently 2 myeloproliferative neoplasms clinical trials recruiting participants in Whittier, CALIFORNIA. These studies are seeking a combined 437 participants. Research is being sponsored by Kartos Therapeutics, Inc.. Clinical trial participation is free and participants receive study-related medical care at no cost.

Myeloproliferative Neoplasms Clinical Trials in Whittier — FAQ

Are there myeloproliferative neoplasms clinical trials in Whittier?

Yes, there are 2 myeloproliferative neoplasms clinical trials currently recruiting in Whittier, CALIFORNIA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Whittier?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Whittier research site will contact you about next steps.

Are clinical trials in Whittier free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Whittier studies also compensate for your time and travel.

What myeloproliferative neoplasms treatments are being tested?

The 2 active trials in Whittier are testing new therapies including novel drugs, biologics, and treatment approaches for myeloproliferative neoplasms.

Data updated March 2, 2026 from ClinicalTrials.gov